These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12742493)

  • 21. Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study.
    Charpentier B; Groth CG; Bäckman L; Morales JM; Calne R; Kreis H; Lang P; Touraine JL; Claesson K; Campistol JM; Durand D; Wramner L; Brattström C;
    Transplant Proc; 2003 May; 35(3 Suppl):58S-61S. PubMed ID: 12742468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus improves the two-year outcome of renal allografts in African-American patients.
    Podder H; Podbielski J; Hussein I; Katz S; Van Buren C; Kahan BD
    Transpl Int; 2001 Jun; 14(3):135-42. PubMed ID: 11499902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection.
    Abdelnoor AM; Ajib R; Chakhtoura M; Daouk M; Medawar W; Uwaydah M; Sawah SI; Khauli RB
    Immunopharmacol Immunotoxicol; 2009; 31(1):83-7. PubMed ID: 18752168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients.
    Hricik DE
    Transplant Proc; 2003 May; 35(3 Suppl):73S-78S. PubMed ID: 12742471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Improved outcome with sirolimus-cyclosporine regimen in high-risk renal transplant recipients].
    Podder H; Forgács B; Csapó Z; Kahan B
    Orv Hetil; 2005 Jul; 146(31):1641-6. PubMed ID: 16158614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
    N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do early cyclosporine levels affect the incidence of acute rejection in renal transplant recipients?
    Johnson EM; Canafax DM; Gillingham K; Schmidt W; Pandian K; Najarian JS; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):879. PubMed ID: 8623444
    [No Abstract]   [Full Text] [Related]  

  • 31. Donor-specific transfusions have long-term beneficial effects for human renal allografts.
    Flye MW; Burton K; Mohanakumar T; Brennan D; Keller C; Goss JA; Sicard GA; Anderson CB
    Transplantation; 1995 Dec; 60(12):1395-401. PubMed ID: 8545863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen.
    Carmellini M; Collini A; Ruggieri G; Bernini M
    Transplant Proc; 2010 May; 42(4):1312-3. PubMed ID: 20534288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.
    Weber M; Deng S; Arenas J; Aradhye S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
    Transplant Proc; 1997 Dec; 29(8):3669-70. PubMed ID: 9414883
    [No Abstract]   [Full Text] [Related]  

  • 34. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M; Banasik M; Patrzalek D; Szyber P; Klinger M
    Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
    Fabrega AJ; Roy G; Reynolds L; Corwin C; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543
    [No Abstract]   [Full Text] [Related]  

  • 37. Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.
    Langer RM; Hong DM; Katz SM; Van Buren CT
    Transplant Proc; 2002 Dec; 34(8):3162-4. PubMed ID: 12493406
    [No Abstract]   [Full Text] [Related]  

  • 38. Preservation of graft function in low-risk living kidney transplant recipients treated with a combination of sirolimus and cyclosporine.
    Machado PG; Felipe CR; Park SI; Garcia R; Moreira S; Casarini D; Franco M; Alfieri F; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2004 Sep; 37(9):1303-12. PubMed ID: 15334195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is sensitivity to cyclosporine influenced by the HLA-DR phenotype of kidney graft recipients?
    Kyriakopoulos G; Antoniadis A; Gakis D; Papanikolaou V
    Transplant Proc; 1996 Dec; 28(6):3294-5. PubMed ID: 8962278
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.